Cancer cells often rely heavily on a nutrient called glutamine for their survival and rapid proliferation. However, these cells are adaptable and can often switch to alternative fuel sources when glutamine is scarce. This metabolic flexibility is a key factor in their ability to evade treatments and continue growing.
New research has revealed that Vitamin B7, also known as biotin, plays a crucial role in enabling this metabolic escape route. Biotin acts like a “license” for cancer cells, facilitating their switch to alternative fuels through a specific key enzyme. Essentially, it unlocks the ability for cancer cells to bypass their glutamine dependence.
Crucially, when biotin is absent, cancer cells lose this essential flexibility. Deprived of their escape mechanisms, they are unable to sustain growth and effectively stop their proliferation. This finding highlights a significant vulnerability in cancer cells that can be exploited for therapeutic purposes.
Furthermore, scientists have identified that mutations within a gene commonly associated with cancer can amplify this dependency on biotin. This means that for certain types of cancer, the absence of biotin could lead to an even more pronounced halt in cell growth, presenting a highly promising new target for cancer therapies.